Okay, here’s a breakdown of the key elements of this extensive forward-looking statement disclaimer. This is a very thorough one, typical for a publicly traded pharmaceutical/biotech company. I’ll categorize the risks and highlight the main themes.
I. Core Forward-Looking Statements (what they are predicting)
* Aramchol Combination therapy: Positive synergy between Aramchol, Stivarga®, and Metformin as a fixed-dose combination for treatment.
* Clinical Trial Timelines: Expectations regarding when clinical trials will occur.
* Clinical Progress: Future plans for developing Aramchol and other candidates.
* Value Creation: Promises of creating value for investors and stakeholders.
* Expansion of Aramchol Use: Development and approval of Aramchol for uses beyond NASH/MASH (non-alcoholic steatohepatitis/metabolic dysfunction-associated steatohepatitis) and fibrosis.
* Commercial Success: Launch and sales of Aramchol and future products.
II. Major Risk Categories (What could go wrong)
Here’s a categorization of the risks, grouped for clarity. I’ve also indicated the relative weight/emphasis based on how much space is devoted to each area in the disclaimer.
A. Regulatory Risks (High Emphasis)
* FDA/EMA Approval: uncertainty around getting approval from the U.S. Food and Drug Governance (FDA) and the European Medicines Authority (EMA). this includes request acceptance, review, approval, and the scope of the approval (what the drug is allowed to treat).
* Post-Market Compliance: Ability to meet ongoing regulatory requirements after a drug is approved.
* Pricing & Reimbursement: Getting favorable pricing for drugs and securing coverage from insurance companies (third-party payors).
B. Clinical & Development Risks (High Emphasis)
* Trial Outcomes: The possibility that pre-clinical and clinical trials won’t be triumphant or will take longer/cost more than expected.
* Expanding Indications: Failure to get approval for uses beyond NASH/MASH.
* Combination Therapy: Challenges in developing and approving Aramchol in combination with other drugs.
C. Financial Risks (Medium Emphasis)
* Capital Requirements: Needing more money than anticipated.
* Financing: Difficulty securing additional funding.
* Market Adoption: Doctors and patients not adopting the drug.
* Commercial Launch Costs: Unexpected costs associated with launching a drug.
* Economic Conditions: Unfavorable economic conditions impacting the business.
* Liquidity Risk: Risks associated with financial institutions.
D. Intellectual Property Risks (Medium emphasis)
* Patent Protection: Inability to adequately protect their inventions.
* Infringement Claims: Being sued for allegedly violating someone else’s patents.
E. Manufacturing & Commercialization Risks (Medium Emphasis)
* Manufacturing: Difficulty producing drugs in sufficient quantities, quality, and at an acceptable cost.
* Sales & Distribution: Building effective sales, marketing, and distribution channels.
* Competition: Intense competition from larger companies with more resources.
F. Strategic & Operational Risks (Low-Medium Emphasis)
* Licensing/Acquisitions: Deals not going as planned.
* Nasdaq Listing: Losing their listing on the Nasdaq stock exchange.
G.Digital Asset/Cryptocurrency Risks (Significant & Emerging – New Risk Area)
* Volatility: The highly volatile nature of cryptocurrency prices.
* Correlation: Share price being heavily influenced by cryptocurrency prices.
* competition: Increased competition in the digital asset space.
* Regulatory Uncertainty: Lack of clear rules and regulations surrounding cryptocurrencies.
* Tax Treatment: Uncertainty about how cryptocurrencies are taxed.
* Digital Asset Management Strategy: Risks associated with their strategy for managing digital assets.
H. Geopolitical Risks (Low-Medium emphasis)
* Middle East Instability: Political and economic instability in the Middle East, specifically mentioning the situation in Israel, possibly harming the business.
III. Significant Caveats & Disclaimers
* Predictions, Not Guarantees: The statements are “onyl current predictions” and are subject to change.
* Known & Unknown Risks: There are risks they know about and risks they don’t know about.
* Material Difference: Actual results could be “materially different” (substantially different) from what’s predicted.
* Don’t Rely on Statements: Investors are warned not to rely on these statements as predictions.
* Further Facts: References to their Annual Report on Form 20-F (filed with the SEC) for more detailed risk information.Specifically, the “Risk Factors” section.
* Dates: The disclaimer references filings from August 25, 2025, and April 2, 2025, indicating this is a future-looking statement as of those dates.
**In essence, this disclaimer is a legal attempt to protect the company from liability if things don’t go as planned.It’s a very standard practice for companies in the biotech
Related reading